Table 2.

Overall efficacy and safety outcomes.

	Overall % (95%CI)
GTR	57.3% (47.5–67.1)
Recurrence	20.7% (16.6–24.8)
PFS 5-y	75.5% (70.0–81.1)
PFS 10-y	49.1% (41.3–56.8)
Vision acuity improvement	57.5% (51.7–63.3)
Proptosis improvement	79.3% (73.7–84.8)
CN focal deficits	20.6% (14.9–26.3)
CSF leak	3.9% (2.3–5.5)
Other	13.9% (10.1–17.7)